Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C41H63NO15.C4H4O4 |
| Molecular Weight | 926.0088 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 20 / 20 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.[H][C@@]12C[C@]34O[C@]5(O)[C@H](CC[C@@]3(C)[C@]5([H])[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@]4([H])[C@]1(O)[C@@H](OC(=O)[C@H](C)CC)[C@H](O)[C@@]6([H])[C@@]2([H])CN7C[C@@H](C)CC[C@@]7([H])[C@@]6(C)O)OC(=O)[C@](C)(O)[C@@H](C)O
InChI
InChIKey=WIWCPBACAHRLCS-VNBGJTSYSA-N
InChI=1S/C41H63NO15.C4H4O4/c1-10-19(3)34(47)56-33-28(46)27-23(17-42-16-18(2)11-12-25(42)38(27,9)50)24-15-39-32(40(24,33)51)30(54-22(6)45)29(53-21(5)44)31-36(39,7)14-13-26(41(31,52)57-39)55-35(48)37(8,49)20(4)43;5-3(6)1-2-4(7)8/h18-20,23-33,43,46,49-52H,10-17H2,1-9H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t18-,19+,20+,23-,24-,25-,26-,27+,28+,29-,30+,31-,32+,33-,36-,37+,38+,39+,40-,41+;/m0./s1
| Molecular Formula | C41H63NO15 |
| Molecular Weight | 809.9366 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 19 / 20 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C4H4O4 |
| Molecular Weight | 116.0722 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
Protoveratrine B is one of two alkaloids isolated from the plant Veratrum albumen. The main effect of both alkaloids is vasodilation in all vascular beds thereby reducing blood pressure. In the 1950's it was recognized that Protoveratrine B is the preferred compound which can be administered at significantly higher doses before the patient begins to vomit.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
402 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19021933/ |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROTOVERATRINE B plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
17 mg multiple, oral Highest studied dose |
unhealthy n = 1 |
Other AEs: Nausea, Vomiting... Other AEs: Nausea Sources: Vomiting Lightheadedness Throat burning sensation of (mild) |
7.5 mg single, oral Highest studied dose |
unhealthy |
|
4.3 ug/kg single, intravenous Highest studied dose Dose: 4.3 ug/kg Route: intravenous Route: single Dose: 4.3 ug/kg Sources: |
unhealthy n = 13 Health Status: unhealthy Condition: hypertension Population Size: 13 Sources: |
Other AEs: Nausea... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Lightheadedness | 17 mg multiple, oral Highest studied dose |
unhealthy n = 1 |
|
| Nausea | 17 mg multiple, oral Highest studied dose |
unhealthy n = 1 |
|
| Vomiting | 17 mg multiple, oral Highest studied dose |
unhealthy n = 1 |
|
| Throat burning sensation of | mild | 17 mg multiple, oral Highest studied dose |
unhealthy n = 1 |
| Nausea | 2 patients | 4.3 ug/kg single, intravenous Highest studied dose Dose: 4.3 ug/kg Route: intravenous Route: single Dose: 4.3 ug/kg Sources: |
unhealthy n = 13 Health Status: unhealthy Condition: hypertension Population Size: 13 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A comparison between protoveratrine A and protoveratrine B orally in arterial hypertension; a therapeutically important difference in activity. | 1956 Dec 20 |
|
| [Protoveratrine A-B in medical therapy of hypertensive disease]. | 1957 Dec 22 |
|
| INHIBITIONS BY OUABAIN AND PROTOVERATRINE ON ACTIVE TRANSPORT OF L-DOPA INTO BRAIN SLICES. | 1963 Apr |
Sample Use Guides
Protoveratrine B was administered to hypertensive patients as an oral tablet. Doses began at 0.3 to 0.5 mg single daily dose and raised incrementally until a marked fall in blood pressure was observed or the development on vomiting prohibited further increase.
Route of Administration:
Oral
Brain cortex slices of adult guinea pig were incubated for 30 min with 0.1 mM L-dopa. Brain slices were then pretreated with 5 uM protoveratrine (10 uM to 10 mM) for 20 min at 27 deg-C. Slices then incubated with glucose and L-dopa at 37 deg-C. The inclusion of Protoveratrine caused a decrease in the accumulation of L-dopa compared to control.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 04:55:26 UTC 2023
by
admin
on
Sat Dec 16 04:55:26 UTC 2023
|
| Record UNII |
ZY7MZX91C8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ZY7MZX91C8
Created by
admin on Sat Dec 16 04:55:26 UTC 2023 , Edited by admin on Sat Dec 16 04:55:26 UTC 2023
|
PRIMARY | |||
|
71587006
Created by
admin on Sat Dec 16 04:55:26 UTC 2023 , Edited by admin on Sat Dec 16 04:55:26 UTC 2023
|
PRIMARY | |||
|
16533-30-5
Created by
admin on Sat Dec 16 04:55:26 UTC 2023 , Edited by admin on Sat Dec 16 04:55:26 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
